Chongqing Zhifei Biological Products Co., Ltd. Share Price

Equities

300122

CNE100000V20

Pharmaceuticals

End-of-day quote Shenzhen S.E. 23:00:00 30/05/2024 BST 5-day change 1st Jan Change
32.8 CNY -0.09% Intraday chart for Chongqing Zhifei Biological Products Co., Ltd. -1.18% -46.33%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 58.19B 8.04B 631B Sales 2025 * 64.49B 8.91B 700B Capitalization 78.52B 10.84B 852B
Net income 2024 * 10.4B 1.44B 113B Net income 2025 * 12.57B 1.74B 136B EV / Sales 2024 * 1.21 x
Net cash position 2024 * 7.86B 1.09B 85.3B Net cash position 2025 * 14.74B 2.04B 160B EV / Sales 2025 * 0.99 x
P/E ratio 2024 *
7.67 x
P/E ratio 2025 *
6.39 x
Employees 6,545
Yield 2024 *
2.79%
Yield 2025 *
3.04%
Free-Float 14.73%
More Fundamentals * Assessed data
Dynamic Chart
Chongqing Zhifei Biological Products' 2023 Profit Rises 7%; Shares Plunge 12% MT
Chongqing Zhifei Biological Products Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Tranche Update on Chongqing Zhifei Biological Products Co., Ltd.'s Equity Buyback Plan announced on February 22, 2024. CI
Chongqing Zhifei Biological Products Co., Ltd.'s Equity Buyback announced on February 22, 2024, has closed with 6,210,253 shares, for CNY 300.01 million. CI
Chongqing Zhifei Biological Products Co., Ltd. announces an Equity Buyback for CNY 500 million worth of its shares. CI
Chongqing Zhifei Biological Products Co., Ltd. authorizes a Buyback Plan. CI
Zhifei Biological Falls After Merck Secures Nod to Market HPV Vaccine in China MT
Zhifei Biological Products to Acquire Local Biopharma Firm, Expanding Into Metabolic Disease Treatments MT
Chongqing Zhifei Biological Products Co., Ltd. signed a letter of intent to acquire Shanghai Polaris Biology Co., Ltd. CI
Chongqing Zhifei Biological Products Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Middle East Conflict Weighs on Exchange-Traded Funds, Equity Futures Pre-Bell Monday MT
GSK Signs Distribution Deal With China's Zhifei for Shingles Vaccine MT
Chongqing Zhifei Biological Enters Exclusive Distribution Deal With GSK MT
Trending : GSK Signs $3 Billion Shingles Vaccine Deal in China DJ
GSK Strikes $3.06 Billion Shingles Vaccine Deal With China's Zhifei -- Update DJ
More news
1 day-0.09%
1 week-1.18%
1 month-6.55%
3 months-38.14%
6 months-49.00%
Current year-46.33%
More quotes
1 week
32.45
Extreme 32.45
33.50
1 month
32.45
Extreme 32.45
37.48
Current year
32.45
Extreme 32.45
61.11
1 year
32.45
Extreme 32.45
70.27
3 years
32.45
Extreme 32.45
133.87
5 years
24.01
Extreme 24.0067
154.13
10 years
5.35
Extreme 5.35
154.13
More quotes
Managers TitleAgeSince
Chairman 43 31/12/13
Director of Finance/CFO 42 31/12/13
Chairman 71 16/08/09
Members of the board TitleAgeSince
Chairman 71 16/08/09
Director/Board Member 44 31/07/12
Director/Board Member 59 10/04/17
More insiders
Date Price Change Volume
31/05/24 32.8 -0.09% 12,763,200
30/05/24 32.83 -0.39% 9,468,116
29/05/24 32.96 -0.18% 9,426,398
28/05/24 33.02 -0.36% 12,138,420
27/05/24 33.14 -0.15% 16,096,680

End-of-day quote Shenzhen S.E., May 30, 2024

More quotes
Chongqing Zhifei Biological Products Co., Ltd. specializes in the research and development of vaccines for human use. The products include, in particular, bacterial vaccines for the prevention of meningitis, tuberculosis, rabies and influenza.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
32.8 CNY
Average target price
58.5 CNY
Spread / Average Target
+78.34%
Consensus
  1. Stock Market
  2. Equities
  3. 300122 Stock